Video Experimental Relacionado
Updated: Jan 8, 2026
07:24
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
1.9K
Hidroxiurea para disminuir el riesgo de accidente cerebrovascular en niños con anemia de células falciformes: una
Emmanuela E Ambrose1, Paul Alikado Sabuni2, Don P Jason Iii3
1Department of Pediatrics and Child Health, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Blood global hematology
|December 24, 2025
Resumen
La hidroxiurea reduce eficazmente el riesgo de accidente cerebrovascular en niños con anemia de células falciformes (ACF) al disminuir las velocidades anormales del flujo sanguíneo. Este tratamiento es una alternativa viable a las transfusiones, especialmente en áreas con recursos limitados.
Área de la Ciencia:
- Hematología pediátrica
- Neurología
- Farmacología
Sus antecedentes:
- La anemia de células falciformes (ACF) es un trastorno hereditario que provoca accidentes cerebrovasculares en niños.
- La ecografía Doppler transcraneal (TCD) evalúa el riesgo de accidente cerebrovascular en pacientes con ACF.
- La prevención actual de accidentes cerebrovasculares incluye transfusiones, que tienen limitaciones en entornos con recursos limitados.
Objetivo del estudio:
- Revisar sistemáticamente la eficacia de la hidroxiurea en la reducción de las velocidades de TCD y el riesgo de accidente cerebrovascular en niños con ACF.
- Aclarar el tamaño del efecto y la duración del impacto de la hidroxiurea en las velocidades de TCD.
Principales métodos:
- Se realizó una revisión sistemática de ensayos clínicos prospectivos en cinco bases de datos médicas importantes.
- Los ensayos incluidos reclutaron niños con ACF, utilizaron cribado TCD y recopilaron datos de velocidad TCD y incidencia de accidentes cerebrovasculares durante la terapia con hidroxiurea.
- Se analizaron datos de 13 ensayos en los que participaron 592 participantes.
Principales resultados:
- La hidroxiurea disminuyó significativamente las velocidades medias de TCD en -30 cm/s durante 0.5 a 2.6 años, con normalización en la mayoría de los niños.
- La incidencia de accidentes cerebrovasculares fue baja (0.52-1.92 por 100 pacientes-año) y ocurrió solo en aquellos con valores de TCD persistentemente altos (>200 cm/s).
- La hidroxiurea demostró ser eficaz en la reducción de las velocidades de TCD y el riesgo asociado de accidente cerebrovascular.
Conclusiones:
- La hidroxiurea es una estrategia eficaz para mitigar el riesgo de accidente cerebrovascular en la ACF pediátrica al reducir las velocidades de TCD.
- Presenta una alternativa factible a las transfusiones de sangre, particularmente beneficiosa en entornos de atención médica con recursos limitados.
- Se necesita más investigación para optimizar la dosificación, evaluar la seguridad a largo plazo y evaluar los beneficios integrales en diversas poblaciones.
Palabras clave:
anemia de células falciformeshidroxiureaaccidente cerebrovascularvelocidad Doppler transcranealhematología pediátricaMás Videos Relacionados
Videos de Conceptos Relacionados
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
01:29Drug Dosing: Infants and Children
229
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
229
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
242
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
242
01:11Renal Failure: Dose Adjustments
401
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
401